Patents Examined by Rebecca Anderson
  • Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders
    Patent number: 9365511
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: June 14, 2016
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Jonathan A. Covel, Albert S. Ren, Graeme Semple, Thuy-Anh Tran, Zheng Wei, Yifeng Xiong
  • Manufacturing process for pyrimidine derivatives
    Patent number: 9359326
    Abstract: The invention relates to processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of such solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: John Vincent Calienni, Baoqing Gong, Prasad Kapa, Hui Liu
  • Aldehyde derivative of substitute oxazolidinones
    Patent number: 9359341
    Abstract: The present invention relates to the prodrug of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, rivaroxaban per se; processes for their preparation, and the application in treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. The prodrug of a compound of formula (B) is chemically designated as 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: June 7, 2016
    Assignee: WANBURY LTD.
    Inventors: Nitin Sharadchandra Pradhan, Nilesh Sudhir Patil, Rajesh Ramchandra Walavalkar, Nilesh Subhas Kulkarni, Sandip Babanrao Pawar, Tarak Sambhaji Pawar
  • Substituted 2,3-dihydro-1-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
    Patent number: 9359315
    Abstract: The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor ?t (ROR?t)/ROR?. The compounds of the present invention are useful for modulating ROR?t)/ROR? activity and for treating diseases or conditions mediated by ROR?t)/ROR? such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: June 7, 2016
    Assignee: Arrien Pharmaceuticals LLC
    Inventors: Hariprasad Vankayalapati, Venkatakrishnareddy Yerramreddy
  • Immune system modulators
    Patent number: 9353115
    Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: May 31, 2016
    Assignee: JANUS BIOTHERAPEUTICS, INC.
    Inventors: Grayson B. Lipford, Charles M. Zepp
  • Heterocyclic compounds and uses thereof in the treatment of sexual disorders
    Patent number: 9353067
    Abstract: Biologically active compounds, which are useful for treating a sexual disorder, are provided herein. Further provided are pharmaceutical compositions formulated for transdermal composition, which comprise a biologically active compound useful for treating a sexual disorder. The compounds and pharmaceutical compositions allow for a prolonged presence of a biologically active compound in plasma. Further provided herein are methods and uses of the compounds and pharmaceutical compositions described herein in the treatment of a sexual disorder, including female sexual disorders.
    Type: Grant
    Filed: December 26, 2011
    Date of Patent: May 31, 2016
    Assignee: ATIR Holding S.A.
    Inventor: Leonid Lurya
  • Polymorphs and salts
    Patent number: 9353098
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
    Patent number: 9353068
    Abstract: The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: May 31, 2016
    Assignee: SANOFI
    Inventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Klaus Wirth
  • Imidazolidinedione compounds and their uses
    Patent number: 9346764
    Abstract: Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. The imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: May 24, 2016
    Assignee: HINOVA PHARMACEUTICALS INC.
    Inventor: Yuanwei Chen
  • Purification method
    Patent number: 9346771
    Abstract: A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Flutemetamol (18F) Injection for the imaging of ?-amyloid plaques in the brain and methods and devices for preparing same are described including the automated synthesis and purification of [18F]flutemetamol by means of solid phase extraction (SPE).
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 24, 2016
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Eric Horn, Steven Fairway, Dimitrios Mantzilas, Nigel Powell
  • Aromatic heterocyclic derivative having TRPV4-inhibiting activity
    Patent number: 9340500
    Abstract: A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I), wherein R1a is substituted or unsubstituted alkyl or the like; R1b is hydrogen or substituted or unsubstituted alkyl; R1c is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted nonaromatic heterocyclic group or the like; -L- is —C(=0)—NR2? or the like; X is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 17, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Akira Yukimasa
  • Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl) acetamide, method for producing the same, and use thereof
    Patent number: 9340516
    Abstract: Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and a method of producing the crystal are provided. The Form-II crystal exhibits diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2? when the spectrum is obtained by using Cu K? radiation: 9.0 degrees, 12.9 degrees, 20.7 degrees, and 22.6 degrees. The Form-II crystal can be produced by crystallizing the subject compound from an alcoholic solvent, a ketone solvent, a saturated hydrocarbon solvent, an ether solvent, water, or a mixture of these solvents. The crystal may be administered as an active ingredient to a subject for the purpose of treating or preventing certain diseases, disorders, and symptoms, or for promoting angiogenesis or gene therapy.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: May 17, 2016
    Assignee: NIPPON SHINYAKU COMPANY, LTD.
    Inventor: Hideyuki Itou
  • Neprilysin inhibitors
    Patent number: 9334245
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: May 10, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
  • Method for preparing dialkyl carbonate
    Patent number: 9334228
    Abstract: Disclosed is a method for preparing a dialkyl carbonate, in which a dialkyl carbonate such as dimethyl carbonate is economically prepared in an environmentally-friendly manner at a higher yield while reducing generation of a by-product. The method for preparing the dialkyl carbonate includes reacting urea, an alkyl carbamate having 1 to 3 carbon atoms, or a mixture thereof with a monovalent alcohol having 1 to 3 carbon atoms in the presence of a room temperature ionic liquid and a catalyst including a salt of a transition metal or a rare earth metal.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 10, 2016
    Assignee: RESEARCH INSTITUTE OF INDUSTRIAL SCIENCE & TECHNOLOGY
    Inventors: Joon Hyun Baik, Jae Cheon Koh, Kyong Tae Kim, Dong Jun Koh, Young Sam Sa, Yun Min Kim, Chul Ung Kim
  • Use of quaternary pyridinium salts as vasoprotective agents
    Patent number: 9333196
    Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 10, 2016
    Assignee: Pharmena Spólka Akcyjna (Pharmena S.A.)
    Inventors: Jerzy Gębicki, Stefan Chłopicki
  • Purine derivatives and their use in the treatment of disease
    Patent number: 9334271
    Abstract: The invention relates to PI3K inhibitors of the formula (I)• in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: May 10, 2016
    Assignee: Novarits AG
    Inventors: Emmanuelle Briard, Pascal Furet, Andreas Lerchner, Peter Meier, Branko Radetich, David Andrew Sandham, Yanyi Zhu
  • Aminopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9321748
    Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: April 26, 2016
    Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
  • Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds
    Patent number: 9321794
    Abstract: The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 26, 2016
    Assignee: CHEMAPOTHECA, LLC
    Inventors: Harold Meckler, Brian Thomas Gregg, Jie Yang
  • Compounds
    Patent number: 9321773
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • HIV protease inhibitors
    Patent number: 9315475
    Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 19, 2016
    Assignees: MERCK SHARP & DOHME CORP., MERCK CANADA INC.
    Inventors: Christian Beaulieu, David J. Bennett, Christopher J. Bungard, Ronald K. Chang, Sheldon Crane, Thomas J. Greshock, Li Hao, Kate Holloway, Jesse J. Manikowski, John A. McCauley, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Philippe G. Nantermet, Christian Nadeau, Satyanarayana Tummanapalli, William Shipe, Sanjay Kumar Singh, Vouy Linh Truong, Sivalenka Vijayasaradhi, Peter D. Williams, Catherine M. Wiscount